Behavioral Health
MAT: Medication-Assisted Treatment for Opioid Use Disorder
MAT combines FDA-approved medications — buprenorphine, methadone, or naltrexone — with counseling and behavioral therapies for opioid use disorder. The evidence-based standard of care endorsed by SAMHSA, NIDA, AMA, and CDC.
The three FDA-approved MAT medications
- Buprenorphine — partial mu-opioid agonist; can be prescribed in office settings (OBOT) by clinicians with appropriate registration.
- Methadone — full mu-opioid agonist; dispensed only at federally certified Opioid Treatment Programs (OTPs).
- Naltrexone — opioid antagonist; available as oral or extended-release injection (Vivitrol). No special prescribing restrictions.
The 2023 X-Waiver elimination
The Mainstreaming Addiction Treatment (MAT) Act eliminated the buprenorphine X-Waiver requirement effective January 2023. Any DEA-registered clinician can now prescribe buprenorphine, dramatically expanding the workforce able to provide OUD treatment in primary care.
MAT analytics views
- Patients on MAT by medication, with treatment retention rates at 6 and 12 months.
- Buprenorphine prescribing patterns by provider — flag opportunities to engage non-prescribers post-X-Waiver elimination.
- HEDIS Pharmacotherapy for Opioid Use Disorder (POD) measure performance.
- Co-occurring behavioral health screening (PHQ-9, GAD-7) for MAT patients.
Where Vizier fits
Vizier reads prescribing data, encounter data, and BH screening data from your EHR connector and surfaces MAT program performance — retention, adherence, comorbid BH outcomes, and HEDIS POD measure tracking.